The ETS-domain transcription factor Elk-1 is a MAP kinase-inducible transcriptional activator protein. However, in the basal state, its activity is repressed by SUMO-dependent histone deacetylase (HDAC) recruitment. Relief of this repression accompanies the activation process. Here, we demonstrate that PIASxa acts to facilitate this derepression process. Members of the PIAS family of proteins can act as E3 enzymes that enhance the sumoylation status of a variety of substrates. However, PIASx-mediated coactivation of Elk-1 occurs in an E3 activity-independent manner. PIASxa binds to Elk-1 in vivo and enhances its transcriptional activity. The coactivating properties of PIASxa require Elk-1 to be modified with SUMO and the integrity of the SUMO binding motif in PIASxa. PIASxa activates Elk-1 through alterations in the HAT/HDAC activities associated with Elk-1. In particular, PIASxa facilitates the loss of the repressive HDAC-2 from sumoylated Elk-1, a key event in the activation of Elk-1 in response to signalling through the ERK MAP kinase pathway. Our data therefore reveal a novel coactivator function for PIASxa through reversing SUMO-mediated repression of transcription factor activity.
Introduction
The modification of proteins by SUMO has recently been shown to play an important role in regulating the activities of a variety of transcriptional regulatory proteins (reviewed in Gill, 2003 Gill, , 2004 Verger et al, 2003) . Generally, protein modification by SUMO imparts repressive properties on these target proteins. Recent studies are beginning to unravel the molecular basis to this repression, and in the case of p300 and Elk-1, sumoylation has been shown to be important for the recruitment of the histone deacetylases HDAC-6 and HDAC-2, respectively (Girdwood et al, 2003; Yang and Sharrocks, 2004) . Furthermore, histone sumoylation has been associated with histone deacetylase recruitment and transcriptional repression (Shiio and Eisenman, 2003) . In other cases such as SP3, sumoylation-dependent changes in subnuclear localisation are thought to contribute to its repressive properties (Ross et al, 2002) .
The ETS-domain transcription factor Elk-1 acts together in a complex with the transcription factor SRF and is rapidly activated by ERK MAP kinase-mediated phosphorylation of its transcriptional activation domain (TAD) in response to mitogenic stimulation (reviewed in Sharrocks, 2002; Shaw and Saxton, 2003) . This modification correlates with the rapid induction of genes, including c-fos, egr-1, mcl-1 and srf (reviewed in Townsend et al, 1999; Sharrocks, 2002; Shaw and Saxton, 2003; Vickers et al, 2004; Kasza et al, 2005) . In addition to a TAD, Elk-1 contains two repression domains, one of which, known as the R-motif contains the sites for SUMO modification Salinas et al, 2004) . This SUMO modification is lost upon activation of the MAP kinase pathway and this loss contributes to the stimulation of the transactivation potential of Elk-1 caused by this pathway . Thus, Elk-1 sumoylation plays an important role in maintaining Elk-1 in a repressed state and has also been shown to reduce its rate of nucleocytoplasmic shuttling (Salinas et al, 2004) .
Protein sumoylation is mediated by a pathway consisting of an E1 SUMO activating enzyme, SAE1/2, and an E2 SUMO conjugating enzyme, Ubc9 (reviewed in Hay, 2001; Muller et al, 2001) . These enzymes are sufficient for substrate sumoylation in vitro. However, recently, a series of proteins have been identified that appear to act to promote substrate sumoylation in an analogous manner to the E3 ligases found in the ubiquitin pathway. These include Pc2 (Kagey et al, 2003) , RanBP2 (Kirsh et al, 2002) and members of the PIAS family (reviewed in Schmidt and Muller, 2003) . The PIAS family is characterised by the presence of a RING finger motif and includes PIAS1, PIAS3, PIASy, PIASxa/b and hZimp10 (reviewed in Schmidt and Muller, 2003) . It is the RING finger motif that imparts E3 ligase activity on the PIAS proteins (Kahyo et al, 2001; Kotaja et al, 2002; Schmidt and Muller, 2002) . In addition, PIAS proteins contain a SAP domain (reviewed in Aravind and Koonin, 2000) and a small motif required for noncovalent binding to SUMO (Kotaja et al, 2002; Song et al, 2004) . Enhanced SUMO modification mediated by PIAS proteins often leads to further reductions in transcription factor activity as demonstrated for PIASxb on p53 (Schmidt and Muller, 2002) . Furthermore, PIAS proteins were first identified by their ability to inhibit the transcriptional activity of STAT proteins (Chung et al, 1997) and this repression needs the sumoylation activity of the PIAS proteins (Rogers et al, 2003; Ungureanu et al, 2003) . However, in some cases, PIAS proteins can activate transcription factors as exemplified by the effects of PIASy on Tcf-4 (Yamamoto et al, 2003) and Zimp10 on the androgen receptor (Sharma et al, 2003) . Again, in both cases, activation is thought to be due to the SUMO ligase activity of the PIAS proteins. However, in the case of p53 activation by PIAS1, the SUMO ligase activity is not required (Megidish et al, 2002) . In addition, PIAS proteins have been shown to affect transcription factor function through altering their subnuclear localisation as shown for the action of PIASy on LEF1 (Sachdev et al, 2001) . The sumoylation activity of PIASy is again important for this process, although the SUMO acceptor sites on LEF1 are not required.
In this study, we have investigated the effect of PIAS proteins on the activity of Elk-1. Instead of the expected role in promoting transcriptional repression through enhanced Elk-1 sumoylation, we demonstrate that PIASxa acts as a coactivator protein. This coactivator activity is independent of its E3 ligase activity but still requires Elk-1 to be SUMO modified. Molecularly, PIASxa activates Elk-1 through altering the HDAC/HAT complexes bound to Elk-1 and facilitating the removal of histone deacetylases.
Results
PIASx proteins upregulate the activity of SUMO-modified Elk-1 Sumoylation of Elk-1 has been shown to repress its transactivation capacity . To begin to probe the potential role of E3 ligases in establishing the repressive state in Elk-1, we first examined the role of PIASx proteins in regulating Elk-1 activity by depletion using RNA interference (RNAi). Western analysis showed that both HeLa and 293 cells expressed only a single PIASx isoform that ran as a doublet on SDS gels, whose molecular weight was consistent with being the alpha isoform ( Figure 1A , and data not shown). siRNA duplexes against PIASxa knocked down the levels of the band corresponding to endogenous PIASxa in HeLa cells (typically 50-90%; Figure 1A , and data not shown) and 293 cells (data not shown), but did not affect the levels of other proteins such as HDAC-2. However, rather than the expected increase in Elk-1-mediated transcriptional activation, which should occur due to decreased sumoylation levels, reductions in PIASxa levels were accompanied by reductions in the transcriptional activity of Elk-1 in both unstimulated and phorbol 12-myristate 13-acetate (PMA)-stimulated cells ( Figure 1B) . However, similar decreases in activity were not seen upon knocking down PIASxa levels with the non-sumoylatable Elk-1(K2R) mutant ( Figure 1C) , suggesting an important role of Elk-1 sumoylation in PIASxamediated coactivation. In contrast, in comparison to the large decrease in Elk-1 activity observed, the activity of the VP16 TAD was only slightly affected by PIASxa depletion ( Figure 1D ).
The functional consequences of PIASxa knockdown on the activity of several Elk-1-regulated target genes were then tested. Reductions in the basal expression of mcl-1, c-fos and srf were observed upon depletion of PIASxa ( Figure 1E ). However, this was not a general effect, as the activity of a different gene, A20 (encoding a zinc-finger protein), was unaffected. The basal level of expression of many Elk-1 target genes is low, making substantial further decreases hard to achieve; therefore, we also examined the effect of depleting PIASxa following PMA-mediated gene activation. PMA signals through the ERK pathway to activate c-fos expression through Elk-1 (reviewed in Shaw and Saxton, 2003) . Reductions in the level of c-fos transcription were again observed in the presence of siRNA against PIASxa under these conditions, consistent with a role of PIASxa in Elk-1-mediated transcriptional activation in response to mitogenic signalling ( Figure 1F ).
As the loss of PIASxa leads to decreased Elk-1 activity, overexpression of PIASxa would be expected to cause the opposite effect and enhance Elk-1 activity. We therefore tested PIASxa and the PIASxb isoform for their ability to promote Elk-1-mediated transcriptional activation. We also tested additional PIAS proteins to exclude nonspecific effects that might occur through perturbation of the SUMO pathway. Both PIASxa and PIASxb enhanced the transactivation capacity of Elk-1 (Figure 2A ). In contrast, neither PIASy nor PIAS1 strongly activated Elk-1, although PIAS1 did show some activating capacity at higher concentrations. PIASxa strongly activated wild-type Elk-1 in a dose-dependent manner but, in comparison, only weakly transactivated a mutant form of Elk-1 that lacks its major SUMO modification sites (Elk-1(K2R); Figure 2B and Supplementary Figure S1 ). To further probe the requirement for Elk-1 sumoylation for coactivation by PIASxa, we carried out reporter gene assays in the presence of a dominant-negative version of Ubc9 (DNUbc9) to inhibit the SUMO pathway. Under these conditions, PIASxa was unable to potentiate Elk-1 transcriptional activity ( Figure 2C ). PIASxa could also potentiate Elk-1 activity under conditions where the ERK MAP kinase pathway was activated by PMA (data not shown), demonstrating that PIASxa can coactivate both basal and 'activated' forms of Elk-1. Furthermore, fusion of SUMO to Elk-1 can permit PIASxa to transactivate an Elk-1 derivative, Elk-1(260-428), which lacks the R-motif containing the SUMO modification sites ( Figure 2D ).
To investigate the specificity of PIASxa action, we tested its activity against the closely related SAP-1 ( Figure 2E ) and the unrelated VP16 ( Figure 2F ) TADs. The activities of both of these transcription factors were unaffected by PIASxa, demonstrating that this is not a general effect on the activity of TADs.
Collectively, these data therefore show that PIASxa can specifically upregulate the activity of Elk-1, but importantly requires Elk-1 to be sumoylated to perform this role. This is fully consistent with the opposite effects mediated by the PIASxa depletion experiments. Thus, loss-of-function and gain-of-function analyses support a role of PIASxa in enhancing the transactivation capacity of SUMO-modified Elk-1 and in promoting target gene activation.
Mapping the regions required for PIASxa-mediated coactivation of Elk-1
To establish the regions of Elk-1 required for coactivation by PIASxa, we first tested a series of truncated Elk-1 derivatives ( Figure 3A) . The R-motif was included in all these constructs as it is essential for PIASxa-mediated coactivation ( Figure 2B and D). PIASxa was unable to potentiate the activity of the N-terminal part of Elk-1, but the coactivation function of PIASxa was retained with the C-terminal part of Elk-1 (Elk-1(205-428)) ( Figure 3B ). The investigation of further C-terminal truncations within the context of demonstrated that upon deletion of the region encompassing the Elk-1 TAD (amino acids 375-399), PIASxa-mediated Elk-1 activation was lost ( Figure 3C ). Thus, it appears that the intrinsic activity of the Elk-1 TAD must be intact for PIASxamediated coactivation. To further probe this, we investigated a series of Elk-1 point mutants, which had diminished transactivation capacity. The mutant Elk-1 proteins F378A/ W379A and I376A/H377A exhibit greatly reduced transactivation capacity when activated by the ERK pathway (Price et al, 1995 ; data not shown) and both show greatly reduced responses to PIASxa-mediated transactivation ( Figure 3D ). In contrast, the more active mutants, V365A/L366A and V412A/D413A, exhibit similar responses to the wild-type protein.
Thus, PIASxa appears to modify the transcriptional output from the Elk-1 TAD rather than providing an additional TAD.
Elk-1 and PIASxa interact in vivo
The coactivating properties of PIASxa suggest that it interacts with Elk-1. To investigate this possibility, we carried out coimmunoprecipitation assays from 293 cells transfected with Elk-1 and PIASxa ( Figure 4A ). Efficient PIASxa precipitation was only observed when both proteins were overexpressed ( Figure 4A , lane 4), although a weaker band can be detected with endogenous levels of Elk-1 ( Figure 4A , lane 2). To demonstrate that endogenous Elk-1 and PIASxa interact, coimmunoprecipitation experiments were performed in HeLa cells. While PIASxa was efficiently precipitated with an Elk-1 antibody, only background levels were observed with normal rabbit IgG ( Figure 4B ). As Elk-1 sumoylation is required for PIASxa-mediated transactivation, we tested whether the SUMO binding motif on PIASxa or the SUMO modification site on Elk-1 is required for PIASxa-Elk-1 interactions. However, neither PIASxa(D467-487) (lacking the SUMO binding motif) ( Figure 4C ) nor the non-sumoylatable Elk-1(K2R) mutant ( Figure 4D ) was deficient in complex formation. Furthermore, cotransfection of the SUMO-specific protease Ssp3 or stimulation with PMA had no effect on complex formation (data not shown). Thus, binding of PIASxa to Elk-1 is not simply through interactions with the SUMO moiety.
To localise the interaction surface on Elk-1, we tested two C-terminal Elk-1 deletion derivatives for PIASxa binding that contained either the intact TAD (Elk(205-399)) or a truncation thereof ). Complexes could readily be detected with Elk(205-399) but, in comparison, interactions were much weaker for Elk(205-375) ( Figure 4E ), demonstrating an important role of residues in the TAD (375-399) in complex formation with PIASxa. This is consistent with the reporter gene analysis, which identified this region as necessary for PIASx-mediated coactivation (Figure 3) . Thus, PIASxa interacts with Elk-1 and this interaction requires the TAD of Elk-1.
Effect of PIASxa on Elk-1 sumoylation and phosphorylation status
Elk-1 transcriptional activity can be enhanced through phosphorylation of its TAD by members of the MAP kinase family (reviewed in Sharrocks, 2002; Shaw and Saxton, 2003) or by interfering with the SUMO modification pathway and loss of SUMO from the R-motif repression domain . We therefore investigated whether PIASxa works through either of these mechanisms. First, we examined the sumoylation status of Elk-1 in the presence of cotransfected PIASxa. However, no decreases in sumoylation levels were observed as would be expected during Elk-1 activation ( Figure 5A ). Next, we tested whether Elk-1 phosphorylation at the critical Ser383 residue is enhanced by PIASxa. However, PIASxa had little effect on Elk-1 phosphorylation ( Figure 5B ). Furthermore, PIASxa-mediated Elk-1 activation was not affected by the ERK pathway inhibitor U01260, demonstrating that PIASxa does not increase Elk-1-mediated transcription by activating the ERK pathway ( Figure 5C ).
To establish whether PIASxa affects the modification status of activated Elk-1, we depleted PIASxa in the presence of PMA stimulation. Activation of the ERK pathway by PMA leads to enhanced Elk-1 phosphorylation and a decrease in Elk-1 sumoylation ( Figure 5D , lanes 1 and 2; Yang et al, 2003) . However, upon depletion of PIASxa, while increases in Elk-1 phosphorylation were unperturbed, the loss of sumoylation was inhibited ( Figure 5D, lanes 3 and 4) . Thus, PIASxa is unimportant for sumoylation and ERK-inducible phosphorylation of Elk-1 but plays an important role in the loss of Elk-1 sumoylation following activation of the ERK pathway. A role in promoting SUMO loss, an activating event, is consistent with our observation that PIASxa is a coactivator of Elk-1.
Mapping the regions of PIASxa involved in coactivation of Elk-1 Next, we determined which regions of PIASxa are important for coactivation of Elk-1. First we studied the activity of two PIASxa mutants, PIASxa(D467-487), which lacks a SUMO binding motif, and PIASxa(W383A), which contains a mutation in the RING finger domain that inhibits its E3 SUMO ligase activity ( Figure 6A ; Kotaja et al, 2002) . Of these mutants, only PIASxa(D467-487) showed a reduced ability to activate Elk-1 ( Figure 6B ). This inability to activate Elk-1 was not due to reduced expression, as PIASxa(D467-487) was expressed to higher levels than the wild-type protein ( Figure 6C ). To further probe a potential defect with PIASxa(W383A), we performed a dose-response experiment with lower levels of PIASxa. However, even at lower concentrations, this mutant was still as active as the wild-type protein (Supplementary Figure S2) . Thus, importantly, the activity of PIASxa(W383A) was unperturbed, indicating that the E3 ligase activity associated with the RING finger is not required for PIASxa-mediated Elk-1 activation.
To further probe the interaction between Elk-1 and PIASxa and its functional consequences, we tested a series of Nterminally deleted PIASxa mutants ( Figure 6A ) for their ability to bind Elk-1 and to activate Elk-1-mediated transcription. In contrast to wild-type PIASxa, binding was much reduced with PIASxa(101-572) ( Figure 6D, lane 2) . The residual binding observed with PIASxa(101-572) was reduced below detectable levels upon further truncation in PIASxa(304-572) ( Figure 6D, lane 3) . To examine the functional consequences of this loss of binding, the activities of the wild-type and truncated versions of PIASxa were tested in a reporter assay using GAL-Elk-1 fusion proteins. In comparison to wild-type PIASxa, PIASxa(101-572) showed reduced transactivation capacity, which was further reduced in PIASxa(304-572) ( Figure 6E ). This reduction in activity was not attributable to differences in expression levels in the reporter assay. Thus, a correlation exists between the ability of Elk-1 and PIASxa to interact and the ability of PIASxa to function as an Elk-1 coactivator. We also tested whether the loss of the SUMO binding motif in PIASxa(D467-487) affected its ability to activate the promoter of an Elk-1-regulated target gene, egr-1. While wild-type PIASxa was able to activate the egr-1 promoter, PIASxa(D467-487) was unable to do so ( Figure 6F ). Furthermore, in the presence of PMA, PIASxa cooperatively enhanced transactivation by Elk-1, while PIASxa(D467-487) was much less effective ( Figure 6G) . Thus, the SUMO binding motif is an important determinant of the coactivating capacity of PIASxa on Elk-1.
PIASxa potentiates p300-mediated coactivation of Elk-1
Transcriptional activation by Elk-1 is mediated, at least in part, through the coactivators p300/CBP (Janknecht and Nordheim, 1996; Li et al, 2003) . We therefore tested whether PIASxa also affected the activity of p300. Increasing concentrations of PIASxa greatly enhanced the activity of p300, but this enhancement was much reduced upon deletion of the CRD1 repression domain in p300DR ( Figure 7A ). The CRD1-motif has previously been shown to be sumoylated (Girdwood et al, 2003) , so this effect is consistent with the role of PIASxa in regulating the activity of other sumoylated transcription factors. Next, we tested which regions of PIASxa are essential for activating p300. The E3 ligasedefective mutant, PIASxa(W383A), activated p300 to similar levels as the wild-type protein ( Figure 7B ). However, deletion of either the SAP domain in PIASxa(103-572) or the SUMO binding motif in PIASxa(D467-487) resulted in reduced levels of activation ( Figure 7B ). The defects observed with PIASxa(103-572) towards p300 were greater than those observed with Elk-1, suggesting that the mode of action is not identical (data not shown).
As PIASxa activates both p300 and Elk-1, we asked whether functional synergy could be observed between the coactivation activities of p300 and PIASxa. Individually, PIASxa and p300 activate Elk-1 five-and 12-fold, respectively ( Figure 7C ). However, together, a synergistic 35-fold activation of Elk-1 is observed. Importantly, this synergism is lost with the non-sumoylatable Elk-1(K2R) mutant that is refractory to PIASxa-mediated coactivation ( Figure 7C ) and is also lost in the presence of the non-sumoylatable p300 mutant p300(D831-1045) ( Figure 7D ). Moreover, a reduction in synergism between PIASxa and p300 is also observed with the PIASxa(D467-487) mutant ( Figure 7E ).
To establish a role of endogenous PIASxa in p300-mediated Elk-1 activation, we compared the coactivating properties of p300 in the absence and presence of siRNAs against PIASxa. The increases in Elk-1 activity elicited by p300 in both the presence and absence of ERK pathway activation were compromised upon depletion of PIASxa ( Figure 7F ). Collectively, these data therefore demonstrate that PIASxa can also act through p300 to affect its coactivator activity and that PIASxa and p300 synergise in coactivation of Elk-1. This synergism is dependent on the sumoylation sites in both p300 and Elk-1 and the SUMO binding site in PIASxa.
PIASxa reduces HDAC activity and promotes increased acetylation at Elk-1 target promoters
The transcriptional activity of Elk-1 has previously been shown to be repressed under basal conditions by the recruitment of HDAC-2 through the repressive R-motif in a SUMOdependent manner (Yang and Sharrocks, 2004) . Furthermore, our results demonstrate that PIASxa coactivation needs Elk-1 to be sumoylated and is required to facilitate SUMO removal from Elk-1 following ERK pathway activation. Thus, a possible molecular mechanism to explain the role of PIASxa would be to promote the loss of HDAC-2 and hence derepression of Elk-1 activity.
To establish whether PIASxa affects the HDAC activity associated with Elk-1, we first investigated the sensitivity of Elk-1 to the HDAC inhibitor trichostatin A (TSA) in the presence and absence of PIASxa. In the presence of PIASxa, Elk-1 became less sensitive to TSA treatment ( Figure 8A ), suggesting a reduced involvement of HDACs in repressing Elk-1 activity. We then tested whether overexpression of a panel of different HDACs was able to reverse PIASxamediated activation ( Figure 8B ). Of the HDACs tested, only HDAC-2, and to a lesser extent HDAC-6, caused a reduction in PIAS-mediated Elk-1 activation. No such effect by HDAC-2 was seen on the Elk-1(K2R) mutant, although a small but reproducible reduction was still observed with HDAC-6 ( Figure 8B ). To further probe a specific role of HDAC-2 in the PIASxa response, we depleted endogenous HDAC-2 by siRNA to investigate whether this sensitised Elk-1 to PIASxamediated transactivation. Depletion of HDAC-2, but not HDAC-3, potentiated the effect of PIASxa on Elk-1 ( Figure 8C ). Again, this effect was not seen on the Elk-1(K2R) mutant.
Together, these results point to a role of PIASxa in specifically affecting HDAC-2 activity associated with Elk-1 and suggest that PIASxa might affect HDAC-2 occupancy at Elk-1-regulated promoters. To test this possibility, we first used chromatin immunoprecipitation (ChIP) analysis to investigate whether PIASxa was recruited to a reporter gene by Elk-1. In the absence of Elk-1, little recruitment of PIASxa could be observed, but was readily detectable in the presence of Elk-1 ( Figure 8D, lanes 1 and 3) . However, while Elk-1 promoted HDAC-2 recruitment, the presence of PIASxa led to a reduction in this recruitment ( Figure 8D, lanes 2 and 3) . To probe the generality of this phenomenon, we also tested the effect of PIASxa on the recruitment of HDAC-6 to p300-regulated promoters. As observed with Elk-1, a loss of HDAC-6 recruitment to a p300-regulated reporter construct was observed upon overexpression of PIASxa ( Figure 8E ). This is consistent with the observation that PIASxa also activates p300-mediated transcriptional activation (Figure 7 ) and demonstrates a wider role of PIASxa in promoting HDAC exclusion from different transcription factor complexes.
To confirm that the PIASxa-mediated HDAC dissociation occurs on endogenous Elk-1-regulated target genes, we examined the presence of HDAC-2 at the c-fos promoter by ChIP analysis ( Figure 8F ). In the presence of PIASxa, HDAC-2 promoter occupancy decreased. Conversely, an increase in histone H4 acetylation was observed, consistent with HDAC loss and promoter activation. Importantly, the PIASxa(D467-487) mutant that cannot activate Elk-1 does not cause a reduction in HDAC-2 occupancy or a change in promoter acetylation status ( Figure 8F ). Finally, we investigated the consequences of depleting endogenous PIASxa on HDAC occupancy and acetylation status of the c-fos promoter. In the absence of siRNAs directed against PIASxa, PMA stimulation enhanced acetylation and decreased HDAC-2 occupancy at the c-fos promoter ( Figure 8G ). In contrast, upon depletion of PIASxa, these PMA-mediated increases in histone acetylation and decreases in HDAC-2 occupancy were blocked. This is consistent with the reductions in c-fos activation observed upon PIASxa depletion ( Figure 1F ). The data are shown relative to GAL-p300 in the absence of PIASxa.
(C-E) Reporter gene analysis of activities of GAL-Elk(1-428) WT and K2R in the presence and absence of the indicated p300 constructs and/or PIASxa proteins and/or PMA on the GAL-driven E1B promoter-reporter construct in COS7 cells. Data are shown relative to the activity of GAL-Elk(1-428) alone (taken as 1). All samples in panels D and E were stimulated with PMA. (F) Reporter assays were carried out in 293 cells in the presence and absence of siRNA duplexes against PIASxa in serum-free (basal) or in stimulated (PMA) conditions. Luciferase assays are representative of at least two independent experiments (standard errors are shown; n ¼ 2).
Collectively, these results therefore demonstrate that a major function of PIASxa is to facilitate HDAC-2 removal from Elk-1 and thereby promote derepression and alter the histone acetylation status of Elk-1-regulated promoters.
Discussion
Recent studies suggest that the modification of transcriptional regulatory proteins by SUMO is a common event and that SUMO modification often imparts transcriptional regulatory properties on the target protein (reviewed in Gill, 2003 Gill, , 2004 Verger et al, 2003) . However, the molecular mechanisms regulating protein sumoylation and the mechanistic actions of SUMO modification are still unclear. Here, we have probed the role of PIAS proteins in Elk-1 regulation, and uncovered an unexpected mode of action. Rather than acting as an E3 ligase to promote transcriptional repression, PIASxa acts as an E3 activity-independent coactivator that facilitates derepression of Elk-1 activity.
Molecularly, PIASxa promotes a switch in the HDAC/HAT activities associated with Elk-1, and hence transcriptional activation. One major point of action is in promoting the loss of HDAC-2 activity associated with Elk-1 ( Figure 8H ). HDAC-2 has previously been shown to play a major role in downregulating the transcriptional activity of Elk-1 (Yang and Sharrocks, 2004) . However, in addition, PIASxa can also upregulate the activity of the Elk-1 coactivator protein p300, thereby increasing the HAT activity associated with Elk-1. This change might also contribute to the change in the acetylation equilibrium mediated by PIASxa. Mechanistically, it appears that PIASxa also works on p300 by HDAC removal, although in this case, its point of action is on HDAC-6, which is specifically recruited by p300 (Girdwood et al, 2003) . This mechanism of action is consistent with the observation that HDAC-6 can partially reverse PIASxa-mediated Elk-1 activation and that this occurs irrespective of the Elk-1 sumoylation status. The overall change in the HDAC/HAT equilibrium is reflected by the changes seen in histone acetylation observed in Elk-1-regulated promoters upon overexpression or depletion of PIASxa and the subsequent gene expression changes observed.
PIAS proteins are characterised as E3 ligases due to the presence of their RING finger domain. Functionally, this has been shown to be important in E3 ligase activity of several PIAS proteins against different substrates (Kahyo et al, 2001; Kotaja et al, 2002; Schmidt and Muller, 2002) . However, the E3 ligase activity of PIASxa is not required for its coactivating activity towards Elk-1 and it does not appear to influence the basal levels of Elk-1 sumoylation. Nevertheless, the action of PIASxa on Elk-1 and p300 requires both substrate sumoylation to occur and also the presence of the SUMO binding motif in PIASxa. This requirement does not reflect a simple need of SUMO binding for recruitment but rather appears to be linked to the major point of action of PIASxa in controlling HDAC binding to Elk-1. As sumoylation is essential for HDAC-2 recruitment to Elk-1 (Yang and Sharrocks, 2004) , this provides an explanation as to why PIASxa-mediated coactivation needs prior Elk-1 sumoylation. In common with many transcription factor targets, Elk-1 is sumoylated at low stoichiometry (1-5%; Yang et al, 2003; Salinas et al, 2004) , yet large functional effects are seen upon disruption of this sumoylation, on both its transactivation capacity and its rate of nucleocytoplasmic shuttling. It has been proposed that this low stoichiometry reflects sumoylation being either a transient trigger or a modification of a transcriptionally relevant subpopulation (Hay, 2005) . The large sumoylationdependent effects we observe on Elk-1 activity due to changes in PIASxa levels further emphasise the importance of this SUMO-modified subpopulation. Furthermore, siRNAmediated depletion experiments demonstrate the importance of PIASxa for SUMO removal from Elk-1. However, it is currently unclear what the temporal order of SUMO and HDAC-2 removal is and whether PIASxa first promotes HDAC-2 removal or whether both occur simultaneously. A possible mode of action of PIASxa would be to affect HDAC-2 or HDAC-6 sumoylation, although to date, neither protein has been shown to be SUMO modified and we have been unable to demonstrate any PIASxa-mediated changes in their sumoylation status (data not shown).
Overall, our results therefore provide a novel molecular role of PIAS proteins in regulating transcription factor activity through mechanisms other than promoting direct substrate sumoylation. Indeed, other studies have shown that PIAS proteins can act in a manner independent of substrate sumoylation, although none have been shown to function molecularly through corepressor/HDAC dissociation. For example, the E3 ligase activity of PIAS1 is not needed for its ability to coactivate p53 (Megidish et al, 2002) . Moreover, the repression of GATA-1 activity by PIASy does not need the SUMO sites in GATA-1 (Collavin et al, 2004) . In addition, the subnuclear relocalisation of LEF1 by PIASy does not require LEF1 sumoylation, although in this case, the sumoylation activity of PIASy is required (Sachdev et al, 2001) . Thus, PIAS proteins have the potential to regulate the activities of transcription factors in a variety of SUMO-dependent and -independent ways.
Elk-1 is activated through phosphorylation in its TAD by the ERK MAP kinase pathway (reviewed in Sharrocks, 2002; Shaw and Saxton, 2003) . Phosphorylation permits recruitment and activation of coactivators like Sur2/Med23 (Stevens et al, 2002) and p300 , but also promotes the loss of SUMO and the loss of associated HDAC-2 (Yang and Sharrocks, 2004 ). PIASxa appears to play an integral role in this process, as overexpression and depletion of PIASxa cause increases and decreases in gene activation mediated by the ERK pathway. These changes in gene activation are accompanied by changes in promoter acetylation. One model to explain the role of PIASxa in this process is that it facilitates HDAC-2 loss during the induction process, which would be followed by SUMO loss ( Figure 8H ). How PIASxa achieves this is unclear, but the requirement for its SUMO binding motif suggests that it might act by engaging the SUMO moiety and displacing components of associated corepressor complexes. The trigger for this might be the conformational change initiated in Elk-1 following its phosphorylation (Yang et al, 1999) , or by a direct effect of the ERK pathway on the activity of PIASxa. Future studies will probe these possibilities.
In summary, our work demonstrates a novel facet of PIAS protein action as a coactivator protein. In the case of Elk-1, PIASxa acts through dynamically regulating the recruitment of HDAC-2. A similar effect is elicited on p300 through HDAC-6 displacement. It will be important to probe the potential roles of PIAS proteins against other substrates to see if the regulation of SUMO site-dependent corepressor complex recruitment is a more widespread phenomenon.
Materials and methods

Plasmid constructs and oligonucelotide primers
For details of plasmids and primers used, see Supplementary data.
Tissue culture, cell transfection, reporter gene assays and RNA interference 293, COS7 and HeLa cells were grown and transfection experiments were carried out as described previously (Yang et al, 2001) . For PMA stimulation, cells were serum-starved for 18 h and subsequently treated with 10 nM PMA for a further 6 h for reporter analysis or for 30 min for ChIP analysis, before harvesting. For TSA experiments, cells were serum-starved for 8 h and subsequently treated with 330 nM of TSA for a further 12 h for reporter analysis before harvesting. Where indicated, 10 mM of the MEK inhibitor, U01260, was added to cells. For Gal4 fusion-driven luciferase reporter gene assays, 0.5 mg of reporter plasmid and 0.25 mg of pCH110 were cotransfected with 0.1 mg of Gal4 fusion expression plasmids. Cell extracts were prepared and luciferase and b-galactosidase assays were carried out as described previously (Yang et al, 1998) .
siRNAs, including the GAPDH control, were constructed by the Silencer TM siRNA construction kit (Ambion). The following were used: HDAC-2 target siRNA sequence: 5 0 -AAGCATCAGGATTCTGT TACG-3 0 ; HDAC-3 target siRNA sequence: 5 0 -AAGATGCTGAACCATG CACCT-3 0 ; human PIASxa-H1 target siRNA sequence: 5 0 -AAGATACT AAGCCCACATTTG-3 0 . To carry out RNAi, a two-step transfection protocol was carried out in 12-well plates as described previously .
SUMO assays in vivo
In vivo sumoylation assays were performed as described previously .
Immunoprecipitation
For immunoprecipitations, the antibody matrix was prepared by binding the antibodies to Dynabeads protein A (rabbit IgG) or protein G (mouse IgG) (Dynal Biotech.). Lysates were prepared from 6 cm dishes in 300 ml of RIPA-1 buffer containing protease inhibitors, 10 mM NEM and E64, as described previously (Kotaja et al, 2002) . The antibody matrix was incubated with whole-cell extracts with rotation overnight at 41C. Complexes were washed three times with RIPA-1, boiled in sample loading buffer and subjected to SDS-PAGE followed by Western blot analysis.
Western blot analysis
Western blotting was carried out with primary antibodies-Flag (Sigma), Elk-1 and Gal4(DBD) (Santa Cruz Biotech.), HA antibody, phospho-Elk (NEB) and PIASxa (kindly provided by J Palvimo)-and HRP-conjugated secondary antibodies (Transduction Lab.) followed by detection with SuperSignal west dura extended duration substrate (Pierce) and visualised using Quantity-One (Bio-Rad).
ChIP assays and quantitative real-time PCR ChIP assay ChIP assays using antisera specific to acetylated histone H4 (Upstate Biotechnology), Elk-1 and HDAC-2 (Santa Cruz Biotech.), HDAC-6 (Abcam) and Flag (Sigma) were performed as described previously (Yang and Sharrocks, 2004) except that crosslinking was performed with 0.5% formaldehyde at room temperature for 2 min and Dynabeads protein A or protein G was used.
Quantitative real-time PCR was performed as specified by the manufacturer using QuantiTect TM SYBR Green PCR reagents (QIAGEN). Data were analysed by Opticon2 (MJ Research).
Real-time RT-PCR
Cells were harvested and total RNA extracted using the RNeasy kit (Qiagen). A 40 ng portion of total RNA from each sample was used for QuantiTect TM SYBR Green RT-PCR kit (QIAGEN) according to the supplier's protocol. Data were analysed by Opticon2 (MJ Research).
Supplementary data
Supplementary data are available at The EMBO Journal Online.
